Core Insights - BGM's stock price increased by 3.86% on August 22, reaching $7.81 per share, with a total market capitalization of $1.437 billion [1] - For the fiscal year ending March 31, 2025, BGM reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while net profit attributable to shareholders was a loss of $0.8612 million, a significant decline of 307.79% compared to the previous year [1] Company Overview - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on innovative solutions in the biopharmaceutical, biorefining, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and agricultural applications [1] - Tetracycline raw materials are used in the production of human antibiotics and support global livestock and aquaculture industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a primary anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are utilized as cough remedies and supplied to retail pharmacies [1]
博美集团上涨3.86%，报7.81美元/股，总市值14.37亿美元